Summary Public Assessment Report

Meriofert Set
(Menotrophin)

DK/H/2356/001-002/DC

2 October 2015

Summary Public Assessment Report

Meriofert Set
Menotrophin, 75 IU and 150 IU powder and solvent for solution for injection

This is a summary of the public assessment report (PAR) for Meriofert Set. It explains how Meriofert Set was assessed and its authorisation recommended as well as its conditions of use. It is not intended to provide practical advice on how to use Meriofert Set.

For practical information about using Meriofert Set, patients should read the package leaflet or contact their doctor or pharmacist.

What is Meriofert Set and what is it used for?

Meriofert Set is used to:

- promote ovulation in women who are not ovulating and who have not responded to other treatment (clomiphene citrate).
- bring about the development of several follicles (and therefore several eggs) in women receiving fertility treatment.

How does Meriofert Set work?

Meriofert Set is a highly purified human menopausal gonadotrophin (HMG), belonging to a group of medicines called gonadotrophins.

Each freeze-dried vial contains 75 IU or 150 IU human follicle stimulating hormone activity (FSH) and 75 IU or 150 IU human luteinising hormone activity (LH).

Human Chorionic Gonadotrophin (hCG), a hormone naturally present in urine of pregnant women, is added to contribute to the total LH activity.

In the ovaries, the FSH-component in HMG induces an increase in the number of growing follicles and stimulates their development. FSH increases the production of oestradiol in the granulosa cells by aromatising androgens that originate in the Theca cells under the influence of the LH-component.

How is Meriofert Set used?

The pharmaceutical form of Meriofert Set is powder and solvent for solution for injection.

Meriofert Set is given by injection under the skin (by the subcutaneous route) or into the muscle (intramuscular injection).

Each vial should be used only once and the injection should be used as soon as it is prepared.

Women who are not ovulating and are having irregular periods or no periods at all:
As a general rule, the first injection of one Meriofert Set 75 IU vial is given during the first week of the cycle after spontaneous or induced menses.
Subsequently, Meriofert Set is injected daily at the dosage prescribed by the physician and the treatment will continue until one or more ripe follicle have developed in the ovary. The

physician will adjust the Meriofert Set dosage depending on the ovarian response, which is determined by clinical examinations.
As soon as one follicle reaches the required development stage, the Meriofert Set treatment will be withheld and ovulation will be triggered with another hormone (chorionic gonadotropin, hCG).
Ovulation generally takes place after 32 to 48 hours.
In this phase of the treatment, fertilization is possible. The patient will be advised to have sexual intercourse every day starting from the day preceding the administration of hCG. If pregnancy is not achieved in spite of ovulation, the treatment can be repeated.

Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive techniques:
The aim of this method is to obtain concomitant multiple follicular development. The treatment will start on the 2nd or 3rd day of the cycle with injections of 150-300 IU of Meriofert Set (1-2 vials of Meriofert Set 150 IU). The physician may decide to administer higher dosages if required. The injected dosage of Meriofert Set is higher than in the method used for natural fertilization. The continuation of the treatment is adjusted individually by the physician.
As soon as a sufficient number of follicles has developed, the treatment with Meriofert Set is withheld and ovulation is triggered by injecting another hormone (chorionic gonadotropin, hCG).

Please read section 3 of the PL for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription.

What benefits of Meriofert Set have been shown in studies?
The company provided its own data on efficacy and safety studies combined with literature references. These studies have shown that Meriofert Set is effective in bringing about the development of several follicles (and therefore several eggs) in women receiving fertility treatment. As for Meriofert Set's use to promote ovulation in women who are not ovulating and who have not responded to other treatment (clomiphene citrate), no formal clinical studies have been performed, but the use is supported by information from the literature.

What are the possible side effects from X?
The most common side effects with Meriofert Set (which may affect more than 1 in 10 people) are headache and swollen or bloated stomach.

Treatment with Meriofert Set should be stopped and a doctor should be consulted immediately if Ovarian Hyperstimulation Syndrome occurs. Symptoms include ovarian cyst formation or enlargement of existing cysts, lower stomach pain, feeling thirsty and sick, and sometimes being sick, passing reduced quantities of concentrated urine and weight gain.

For the full list of all side effects reported with Meriofert Set, see section 4 of the package leaflet.

Meriofert Set should not be used in case of:
- Enlarged ovaries or cysts not caused by a hormonal disorder (polycystic ovarian disease).
- Bleeding of unknown cause.
- Cancer of the ovaries, uterus or breast.
- Abnormal swelling (tumour) of the pituitary gland or hypothalamus (brain).

- Early menopause, a malformation of the sexual organs or certain tumours of the womb that would make a normal pregnancy impossible.

For the full list of restrictions, see the package leaflet.

Why is Meriofert Set approved?
Clinical experience with urine derived and recombinant human gonadotropins is extensive and the clinical safety of these drugs is known.

It was concluded that Meriofert Set's benefits are greater than its risks and recommended that it be approved for use.

What measures are being taken to ensure the safe and effective use of Meriofert Set?
A risk management plan has been developed to ensure that Meriofert Set is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Meriofert Set, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Meriofert Set
The marketing authorisation for Meriofert Set was granted on 5 February 2015.

The full PAR for Meriofert Set can be found on the website http://mri.medagencies.org/Human/. For more information about treatment with Meriofert Set, read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 10-2015.